Literature DB >> 15372214

RNA interference: potential therapeutic targets.

S Jana1, C Chakraborty, S Nandi, J K Deb.   

Abstract

One of the most exciting findings in recent years has been the discovery of RNA interference (RNAi). RNAi methodologies hold the promise to selectively inhibit gene expression in mammals. RNAi is an innate cellular process activated when a double-stranded RNA (dsRNA) molecule of greater than 19 duplex nucleotides enters the cell, causing the degradation of not only the invading dsRNA molecule, but also single-stranded (ssRNAs) RNAs of identical sequences, including endogenous mRNAs. The use of RNAi for genetic-based therapies has been widely studied, especially in viral infections, cancers, and inherited genetic disorders. As such, RNAi technology is a potentially useful method to develop highly specific dsRNA-based gene-silencing therapeutics.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15372214     DOI： 10.1007/s00253-004-1732-1

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN： 0175-7598            Impact factor:   4.813


  11 in total

Review 1.  Lipid-based vectors for siRNA delivery.

Authors:  Shubiao Zhang; Defu Zhi; Leaf Huang
Journal:  J Drug Target       Date:  2012-09-20       Impact factor: 5.121

2.  EMMPRIN reduction via scFv-M6-1B9 intrabody affects α3β1-integrin and MCT1 functions and results in suppression of progressive phenotype in the colorectal cancer cell line Caco-2.

Authors:  S Sangboonruang; P Thammasit; N Intasai; W Kasinrerk; C Tayapiwatana; K Tragoolpua
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

3.  Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.

Authors:  Shyh-Dar Li; Sumio Chono; Leaf Huang
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

4.  Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both in vitro and in vivo.

Authors:  Weizao Chen; Mingqiu Liu; Ye Jiao; Weiyao Yan; Xuefeng Wei; Jiulian Chen; Liang Fei; Yang Liu; Xiaoping Zuo; Fugui Yang; Yonggan Lu; Zhaoxin Zheng
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

5.  Tumor-targeted delivery of siRNA by self-assembled nanoparticles.

Authors:  Shyh-Dar Li; Yun-Ching Chen; Michael J Hackett; Leaf Huang
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

Review 6.  Nonviral methods for siRNA delivery.

Authors:  Kun Gao; Leaf Huang
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 7.  Insights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic intervention.

Authors:  Wafaa M Ezzat; Khalda Sayed Amr
Journal:  World J Hepatol       Date:  2016-10-28

Review 8.  Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; C George Priya Doss; Sang-Soo Lee
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-12       Impact factor: 8.886

9.  Inhibition of porcine hemagglutinating encephalomyelitis virus replication by short hairpin RNAs targeting of the nucleocapsid gene in a porcine kidney cell line.

Authors:  Yungang Lan; Kui Zhao; Wenqi He; Gaili Wang; Huijun Lu; Deguang Song; Feng Gao
Journal:  J Virol Methods       Date:  2011-11-26       Impact factor: 2.014

10.  In vitro inhibition of CSFV replication by retroviral vector-mediated RNA interference.

Authors:  Jiangnan Li; Huancheng Guo; Zixue Shi; Changchun Tu
Journal:  J Virol Methods       Date:  2010-08-04       Impact factor: 2.014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.